Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy

Journal of the National Cancer Institute

Volumn 98, Issue 19, 2006, Pages 1420-1424

  Henshall, Susan M ^a   Horvath, Lisa G ^a,b   Quinn, David I ^d   Eggleton, Sarah A ^a   Grygiel, John J ^a   Stricker, Phillip D ^a   Biankin, Andrew V ^a,e   Kench, James G ^a,c   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 GLYCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ZINC; ZINC ALPHA2 GLYCOPROTEIN;

ARTICLE; BONE METASTASIS; CANCER MORTALITY; CANCER RECURRENCE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS POTENTIAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION; RELIABILITY; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; VALIDATION PROCESS;

AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT; RNA; SEMINAL PLASMA PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749542697     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj378     Document Type: Article

References (18)

1. Quinn DI, Henshall S, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-87.
2. D'Amico A, Moul JW, Carroll P, Sun L, Lubeck D, Chen M-H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-83.
3. Freedland S, Humphreys E, Mangold L, Eisenberger M, Dorey F, Walsh P, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-9.
4. Slovin S, Wilton A, Heller G, Scher H. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005;11:8669-73.
5. Stouffer S, Suchman E, DeVinney L, Star S, Williams RM Jr. The American soldier: Adjustment during army life. Princeton (NJ): Princeton University Press; 1949.
6. Becker B. Combining significance levels. In: Cooper H, Hedges L, editors. The handbook of research synthesis. New York (NY): Russell Sage Foundation; 1994. pp. 215-30.
7. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
8. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-203.
9. Lapointe J, Lid C, Higgins J, van de Rijna M, Baire E, Montgomerya K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
10. Sanchez L, Lopez-Otin C, Bjorkman P. Biochemical characterization and crystalization of human Zn-alpha2-glycoprotein, a soluble class I major histocompatibility complex homolog. Proc Natl Acad Sci U S A 1997,94:4626-30.
11. Hale L, Price D, Sanchez L, Demark-Wahnefried W, Madden J. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001;7: 846-53.
12. Quinn DI, Henshall SM, Haynes A-M, Brenner PC, Kooner R, Golovsky D, et al. Prognostic significance of pathological features in localized prostate cancer treated with radical prostatectomy: Implications for staging systems and predictive models. J Clin Oncol 2001;19:3692-705.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
14. Cox DR. Regression models and life tables (life tables). J R Stat Soc 1972;34:187-9.
15. Cannon G, Walsh P, Partin A, Pound C. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. J Urol 2003; 62:2-8.
16. Nelson P, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002;99:11890-5.
17. Chalbos D, Haagensen D, Pwish T, Rochefort H. Identification and androgen regulation of two proteins released by T47D human breast cancer cells. Cancer Res 1987;47:2787-92.
18. Daneshmand S, Quek M, Stein J, Liekovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 2004;172:2252-5.